Celladon is dedicated to the treatment of cardiac diseases through the use of new technologies in molecular cardiology. Celladon’s products are first-in-class drugs that target the key enzyme deficiency in severe heart failure, SERCA2a. A major underpinning of heart failure is the depletion of SERCA2a enzyme in heart muscle cells, which results in abnormal intracellular calcium cycling and poor contractility. Our research shows that recombinant adeno-associated viral (AAV) vectors are ideal for restoring SERCA2a enzyme production via gene transfer to cardiac muscle cells.
Click on the links below for Celladon's Product Overview.
Wednesday, May 8, 2013
Celladon and SIRO Clinpharm Announce Presentation at “Statisticians in the Pharmaceutical Industry International Conference”
Tuesday, May 7, 2013
Celladon is a Finalist for the 2013 Red Herring Top 100 North America Award
Heartening Results: The CUPID Gene Therapy Trial for Heart Failure